Drug Trial Radar · NCT07939919
A Study of AK158D1 in Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
349
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Apr 30, 2028
Study completion Apr 30, 2030
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics and preliminary antitumor efficacy of AK158D1 in advanced solid tumors.
Conditions
- Solid Malignant Tumor
Interventions
AK158D1Drug
Subjects will receive AK158D1 via intravenous infusion (IV) in prespecified dose levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 21 days)
- Adverse Events (AEs)Time frame: Up to approximately 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.